Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. van der Veer A, et al. Among authors: escherich g. Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23. Blood. 2013. PMID: 23974192 Free PMC article.
High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia.
Troeger A, Gudowius S, Escherich G, den Boer ML, Glouchkova L, Ackermann B, Meisel R, Laws HJ, Groeger M, Wessalowski R, Willers R, Harbott J, Pieters R, Goebel U, Janka-Schaub GE, Hanenberg H, Dilloo D. Troeger A, et al. Among authors: escherich g. Br J Haematol. 2007 Nov;139(3):450-7. doi: 10.1111/j.1365-2141.2007.06818.x. Br J Haematol. 2007. PMID: 17910636 Free article.
High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95.
Troeger A, Glouchkova L, Ackermann B, Escherich G, Meisel R, Hanenberg H, den Boer ML, Pieters R, Janka-Schaub GE, Goebel U, Laws HJ, Dilloo D. Troeger A, et al. Among authors: escherich g. Blood. 2008 Aug 15;112(4):1028-34. doi: 10.1182/blood-2007-11-123315. Epub 2008 Jun 13. Blood. 2008. PMID: 18552209 Free article.
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui CH, Valsecchi MG. Aricò M, et al. Among authors: escherich g. J Clin Oncol. 2010 Nov 1;28(31):4755-61. doi: 10.1200/JCO.2010.30.1325. Epub 2010 Sep 27. J Clin Oncol. 2010. PMID: 20876426 Free PMC article.
The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Escherich G, Tröger A, Göbel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, zur Stadt U, Kazemier K, Pieters R, Den Boer ML, Horstmann M, Janka GE; CoALL study group, Hamburg, Germany. Escherich G, et al. Haematologica. 2011 Jun;96(6):854-62. doi: 10.3324/haematol.2010.039735. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330320 Free PMC article.
162 results